在怀孕期间导航原发性免疫性血小板缺血:管理策略和考虑:全面的审查
Bhavana V Waghmare1, Shubhada Jajoo1
1Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus
|September 20, 2024
概括
在怀孕期间管理免疫血小板缺血症 (ITP) 需要平衡母亲和胎儿的健康. 本综述详细介绍了ITP的病理生理学,诊断和治疗方法,包括皮质类固醇和IVIG,以获得最佳的结果.
科学领域:
- 产科和妇科 产科和妇科
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 初级免疫性血小板缺血 (ITP) 是一种自身免疫性疾病,导致血小板数量低.
- 怀孕期间的ITP对母亲和胎儿的健康构成独特的挑战.
研究的目的:
- 综合审查孕妇ITP的病理生理学,诊断和管理.
- 讨论新兴的治疗方法和未来的研究方向,用于怀孕期间的ITP.
主要方法:
- 一个彻底的文献综述流行病学,病理生理学,诊断标准和怀孕期间ITP的治疗选择.
- 审查相关的临床指南和专家共识.
主要成果:
- 管理需要一个多学科的方法与个性化的计划.
- 第一线治疗包括皮质类固醇和IVIG;对于耐火病例,存在二线选择.
- 治疗决策考虑血小板缺血的严重程度,出血症状,妊娠年龄和新生儿风险.
结论:
- 怀孕期间的ITP需要平衡母亲的治疗与胎儿的保护.
- 量身定制的管理策略对于最小化风险和优化结果至关重要.
- 需要进一步的研究来推进对患有ITP的孕妇的护理.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
496
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
496
Anticoagulant Drugs: Low-Molecular-Weight Heparins
649
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
649
Development of Immunocompetence
294
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
294


